An analysis of the CIBMTR database of 182 ALCL patients receiving allo-HCT that similarly did not separate patients based on ALK status did find that allo-HCT for relapsed/refractory ALCL had a 5-year pFS of 41% and OS of 56%, indicating that allo-HCT can play an effective role in treating relapsed/refractory disease37. Here, ALK is linked to anaplastic large cell lymphoma.